Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 6/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21058384 | 0.89 | SSTR5 (0.47) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL21058383 | 0.88 | SSTR5 (0.53) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL21058369 | 0.86 | SSTR5 (0.54) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL21058365 | 0.81 | SSTR3 (0.58) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL21058359 | 0.80 | LMNA (0.48) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL21058337 | 0.80 | SSTR5 (0.56) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL21058364 | 0.79 | SSTR3 (0.55) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL31352990 | 0.79 | LMNA (0.50) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL10961242 | 0.79 | MCHR1 (0.47) | SSTR5SSTR3SSTR2SSTR4SSTR1 | |
| SCHEMBL10960734 | 0.79 | MCHR1 (0.48) | SSTR5SSTR3SSTR2SSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | SSTR5 684/4885SSTR3 1029/4885SSTR2 1327/4885 |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, FUT6 | SSTR5 1333/4885SSTR3 1657/4885SSTR2 2139/4885 |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | SOST, FUT6, SLC5A1 | SSTR5 2999/4885SSTR3 2990/4885SSTR2 3427/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | SSTR5 684/4885SSTR3 1029/4885SSTR2 1327/4885 |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | SSTR5 684/4885SSTR3 1029/4885SSTR2 1327/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | SSTR5 684/4885SSTR3 1029/4885SSTR2 1327/4885 |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, FUT6 | SSTR5 1333/4885SSTR3 1657/4885SSTR2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.